S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
OTCMKTS:HCYTD

H-CYTE (HCYTD) Stock Forecast, Price & News

$2.02
-1.98 (-49.50%)
(As of 07/11/2022)
Compare
Today's Range
$2.02
▼
$2.77
50-Day Range
$2.02
▼
$2.02
52-Week Range
$2.02
▼
$77.00
Volume
400 shs
Average Volume
103 shs
Market Capitalization
$521,160.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest

HCYTD stock logo

About H-CYTE (OTCMKTS:HCYTD) Stock

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

HCYTD Price History

HCYTD Stock News Headlines

June 14, 2023 | forbes.com
H-E-B Grocery Company
May 12, 2023 | marketwatch.com
10-K: H-CYTE, INC.
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
March 24, 2023 | seekingalpha.com
HCYT H-CYTE, Inc.
September 8, 2022 | finance.yahoo.com
H-CYTE Completes Acquisition of Jantibody
July 23, 2022 | apnews.com
H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days
June 13, 2022 | finance.yahoo.com
H-CYTE Announces 1-for-1,000 Reverse Stock Split
March 6, 2022 | yahoo.com
Should You Refrigerate Peanut Butter?
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
March 6, 2022 | yahoo.com
Netflix’s new superhero show might be the weirdest thing you ever watch
March 4, 2022 | finance.yahoo.com
H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise
February 7, 2022 | nasdaq.com
H-CYTE Inc (HCYT)
January 11, 2022 | seekingalpha.com
H-CYTE signs letter of intent to acquire Catheter Precision
January 11, 2022 | finance.yahoo.com
H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.
December 6, 2021 | finance.yahoo.com
H-CYTE Names Michael Yurkowsky Chief Executive Officer
September 9, 2021 | au.finance.yahoo.com
Italian court seeks opinion on Berlusconi's health due to trial delays
September 8, 2021 | finance.yahoo.com
H-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health
July 7, 2021 | ca.finance.yahoo.com
Jefferson Lines takes proactive steps toward crisis management with TSA I-STEP training
July 7, 2021 | in.finance.yahoo.com
Scanfil plc: Managers' transactions – Jokitalo
July 6, 2021 | finance.yahoo.com
H-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung Health
July 1, 2021 | in.finance.yahoo.com
Constellium supplies advanced aluminium solutions for the electric Audi e-tron GT
July 1, 2021 | au.finance.yahoo.com
NetNumber Named as One of the “10 Most Disruptive Companies of 2021” by Exceleon Magazine
June 29, 2021 | finance.yahoo.com
H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung Health
October 4, 2020 | msn.com
New Providence CEO: 'We have a responsibility and accountability to the community'
September 29, 2020 | feeds.benzinga.com
Robert Greif named Chief Executive Officer of H-CYTE
September 27, 2020 | marketwatch.com
Three Canada Stocks who's Volume Surged on Bullish Signals: $VS $PPR $QRO
September 2, 2020 | finance.yahoo.com
H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020
See More Headlines
Receive HCYTD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter.

HCYTD Company Calendar

Today
9/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HCYTD
CUSIP
N/A
CIK
1591165
Web
www.hcyte.com
Phone
(844) 633-6839
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,800,000.00
Net Margins
-450.40%
Pretax Margin
-450.40%
Return on Equity
N/A
Return on Assets
-777.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.12
Quick Ratio
0.12

Sales & Book Value

Annual Sales
$1.61 million
Price / Sales
0.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($31.45) per share
Price / Book
-0.06

Miscellaneous

Outstanding Shares
258,000
Free Float
244,000
Market Cap
$521,160.00
Optionable
Not Optionable
Beta
1.12
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Michael W. Yurkowsky (Age 50)
    CEO & Director
    Comp: $180k
  • Mr. Jeremy Daniel (Age 46)
    Chief Financial Officer
    Comp: $200k
  • Dr. Tanya Rhodes Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $252k
  • Mr. Jeffery Wright CPA (Age 39)
    CPA, Controller & Principal Accounting Officer

Key Competitors

View All Competitors













HCYTD Stock - Frequently Asked Questions

How have HCYTD shares performed in 2023?

H-CYTE's stock was trading at $2.02 at the start of the year. Since then, HCYTD stock has increased by 0.0% and is now trading at $2.02.
View the best growth stocks for 2023 here.

What is H-CYTE's stock symbol?

H-CYTE trades on the OTCMKTS under the ticker symbol "HCYTD."

How do I buy shares of H-CYTE?

Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is H-CYTE's stock price today?

One share of HCYTD stock can currently be purchased for approximately $2.02.

How much money does H-CYTE make?

H-CYTE (OTCMKTS:HCYTD) has a market capitalization of $521,160.00 and generates $1.61 million in revenue each year.

How can I contact H-CYTE?

H-CYTE's mailing address is 201 E Kennedy Blvd Suite 700, Tampa FL, 33602. The official website for the company is www.hcyte.com. The company can be reached via phone at (844) 633-6839 or via email at jassad@hcyte.com.

This page (OTCMKTS:HCYTD) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -